A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

NCT01296971 · clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped study was not started due to an administrative reason on the part of the local Health Authority

Conditions

Interventions

Sponsor

Hoffmann-La Roche